SSG
AGIO icon

Summit Securities Group’s Agios Pharmaceuticals AGIO Stock Holding History

Summit Securities Group’s Portfolio AGIO Stock Details AGIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-408
Closed -$13.8K – 1141
2026
Q1 		$13.8K Buy
+408
New +$11.6K ﹤0.01% 601
2013
Q4 		– Sell
-100
Closed -$3K – 508
2013
Q3 		$3K Buy
+100
New +$2.76K ﹤0.01% 318

Other funds holding AGIO

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $66.6B AUM

Summit Securities Group's AGIO Position: Q2 2026 in Review

Summit Securities Group sold out of Agios Pharmaceuticals (AGIO) in Q2 2026, closing a stake of 408 shares — an estimated $13.8K sold.

Summit Securities Group first reported a position in AGIO in Q3 2013 and held it in 2 quarters. The position peaked at $13.8K in Q1 2026. 239 funds tracked by Wall St. Rank hold AGIO as of Q2 2026.

  • Summit Securities Group reported no remaining Agios Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Summit Securities Group sold 408 Agios Pharmaceuticals shares in Q2 2026, an estimated $13.8K.
  • Summit Securities Group first reported a position in Agios Pharmaceuticals in Q3 2013 and held it in 2 quarters.
  • Summit Securities Group's Agios Pharmaceuticals position peaked at $13.8K in Q1 2026.
  • 239 funds tracked by Wall St. Rank held Agios Pharmaceuticals as of Q2 2026.

Based on Summit Securities Group's 13F filing for Q2 2026, filed 3 Aug 2026.